Investment: Should you invest in... pharmaceutical companies?

the pharmaceuticals sector has been a source of strong growth, despite the potentially high-risk nature of a business heavily dependent on research and development of new products, and patent protection. The more mature business of chemicals manufacture has also been largely out of favour.

Glenn Meyer of Pavilion Asset Management says: "The two sectors seem to act in opposition. Pharmaceuticals are generally growth stocks and chemical companies tend to be highly cyclical. Pharmaceuticals have a much clearer and longer flow of earnings, and the chemical sector moves in line with the world economy and is much more volatile."

Jeremy Batstone of NatWest Stockbrokers has a different focus."Pharmaceuticals have been very volatile and the sector has tended to lag the market," he says. "People are looking more for value as the economy has improved, away from more defensive growth areas like pharmaceuticals."

Mark Mathias, head of investment funds at Rea Brothers Investment Management, agrees the sector's long-term growth potential is undisputed. Mathias, whose firm runs two specialist pharmaceutical funds, says: "There is the trend to ageing populations in the OECD countries, with the highest proportion of lifetime healthcare expenditure coming in the last two years of life, underpinned by the significant increase in healthcare research expenditure. At the same time, the OECD governments are trying to rein in the cost of government-subsidised healthcare and the way you do that is to spend more on drugs to keep people out of hospital."

North America's political debate about state-funded medical programmes has added to the uncertainty, says Nigel Thomas, manager of ABN Amro's UK Growth Fund. "Proposed legislation in Medicare reform will limit spending on outpatient drug costs for elderly people who account for over 30 per cent of US outpatient drug spending and this will affect pharmaceutical companies - the FT suggests it would impact earnings by between 10 and 15 per cent."

Thomas says the plans will probably not come to fruition but the debate is affecting share prices. "It is a political hot potato but given the Republican position in Congress, we are not so sure it will be enacted."

Size is also going to be a key element in future corporate earnings. "When it comes down to it, healthcare is not an optional expenditure and the amounts spent on it are going to rise," adds Mathias.

"There is very good long-term earnings visibility in the pharmaceutical sector andmergers of large companies. You can sell the same drugs into different markets, and IT helps keep control in multinational companies."

Batstone says: "There is still a lot of scope for mergers and acquisitions in the pharmaceutical sector. Critical mass is the key force driving consolidation because of the large spend on R&D. The quicker you can develop a new drug from scratch, the longer you will have the benefit of its patent protection, but without the scale you haven't got the size or funds for research."

Every major player is in the frame. "SmithKline Beecham is mentioned on a fairly regular basis but Glaxo Wellcome is also rumoured to be looking at an overseas tie-up," he adds.

Glenn Meyer says: "The UK chemical sector has underperformed the market, but overseas firms seem to value UK chemical companies more highly than the market does."

Stock selection is the key. "Concentrate on chemical sector stocks which focus on profitable areas, such as BTP, which constantly refreshes its portfolio," he says. "Avoid larger companies, which tend to underperform the market."

There is scope for the active share trader. Meyer adds: "ICI has been a relatively poor performer for a long time, but with short periods of outperformance, so timing is everything. Look at manufacturers of industrial chemicals. The problem here is that you very quickly reach overcapacity and have a fairly low return on capital."

By contrast, the bulk of investor interest in the drugs sector is focused on the largest stocks. Nigel Thomas says: "There aren't that many pure pharmaceutical companies below pounds 1bn in size. Shire Pharmaceuticals and Medeva, with Galen in Ireland, are the only mid-sized ones and once below a certain size they are largely bio-techs, of which we like Celltech and Phytopharm."

Jeremy Batstone adds: "There are a lot of stocks in the sector relatively cheap, with the possible exception of AstraZeneca. Glaxo Wellcome still looks good value at around pounds 19. We would suggest it could get up to maybe pounds 21.50 or pounds 22 in the short to medium term."

Another key player in the sector is SmithKline Beecham, where investors were holding off until the US Food & Drug Administration (FDA) ruled on Avandia, its new diabetes treatment, last week. Batstone adds: "The ruling was positive and SmithKline could be looking at sales of $1.5bn to $2bn."

Start your day with The Independent, sign up for daily news emails
News
ebookA unique anthology of reporting and analysis of a crucial period of history
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Guru Careers: Pricing Analyst

£30 - 35k: Guru Careers: We are seeking a Pricing Analyst to join a leading e-...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £45K YR1: SThree: At SThree, we like to be dif...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...

Guru Careers: C# Project Team Lead

£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...

Day In a Page

Fifa corruption: The 161-page dossier that exposes the organisation's dark heart

The 161-page dossier that exposes Fifa's dark heart

How did a group of corrupt officials turn football’s governing body into what was, in essence, a criminal enterprise? Chris Green and David Connett reveal all
Mediterranean migrant crisis: 'If Europe thinks bombing boats will stop smuggling, it will not. We will defend ourselves,' says Tripoli PM

Exclusive interview with Tripoli PM Khalifa al-Ghweil

'If Europe thinks bombing boats will stop smuggling, it will not. We will defend ourselves'
Raymond Chandler's Los Angeles: How the author foretold the Californian water crisis

Raymond Chandler's Los Angeles

How the author foretold the Californian water crisis
Chinese artist who posted funny image of President Xi Jinping facing five years in prison as authorities crackdown on dissent in the arts

Art attack

Chinese artist who posted funny image of President Xi Jinping facing five years in prison
Marc Jacobs is putting Cher in the limelight as the face of his latest campaign

Cher is the new face of Marc Jacobs

Alexander Fury explains why designers are turning to august stars to front their lines
Parents of six-year-old who beat leukaemia plan to climb Ben Nevis for cancer charity

'I'm climbing Ben Nevis for my daughter'

Karen Attwood's young daughter Yasmin beat cancer. Now her family is about to take on a new challenge - scaling Ben Nevis to help other children
10 best wedding gift ideas

It's that time of year again... 10 best wedding gift ideas

Forget that fancy toaster, we've gone off-list to find memorable gifts that will last a lifetime
Paul Scholes column: With the Premier League over for another year, here are my end of season awards

Paul Scholes column

With the Premier League over for another year, here are my end of season awards
Heysel disaster 30th anniversary: Liverpool have seen too much tragedy to forget fateful day in Belgium

Liverpool have seen too much tragedy to forget Heysel

Thirty years ago, 39 fans waiting to watch a European Cup final died as a result of a fatal cocktail of circumstances. Ian Herbert looks at how a club dealt with this tragedy
Amir Khan vs Chris Algieri: Khan’s audition for Floyd Mayweather may turn into a no-win situation, says Frank Warren

Khan’s audition for Mayweather may turn into a no-win situation

The Bolton fighter could be damned if he dazzles and damned if he doesn’t against Algieri, the man last seen being decked six times by Pacquiao, says Frank Warren
Blundering Tony Blair quits as Middle East peace envoy – only Israel will miss him

Blundering Blair quits as Middle East peace envoy – only Israel will miss him

For Arabs – and for Britons who lost their loved ones in his shambolic war in Iraq – his appointment was an insult, says Robert Fisk
Fifa corruption arrests: All hail the Feds for riding to football's rescue

Fifa corruption arrests

All hail the Feds for riding to football's rescue, says Ian Herbert
Isis in Syria: The Kurdish enclave still resisting the tyranny of President Assad and militant fighters

The Kurdish enclave still resisting the tyranny of Assad and Isis

In Syrian Kurdish cantons along the Turkish border, the progressive aims of the 2011 uprising are being enacted despite the war. Patrick Cockburn returns to Amuda
How I survived Cambodia's Killing Fields: Acclaimed surgeon SreyRam Kuy celebrates her mother's determination to escape the US

How I survived Cambodia's Killing Fields

Acclaimed surgeon SreyRam Kuy celebrates her mother's determination to escape to the US
Stephen Mangan interview: From posh buffoon to pregnant dad, the actor has quite a range

How Stephen Mangan got his range

Posh buffoon, hapless writer, pregnant dad - Mangan is certainly a versatile actor